Otofarma S.p.A. — Board/Management Information 2026

Jan 8, 2026

Data/Ora Ricezione : 8 Gennaio 2026 08:00:02

Oggetto : Otofarma: Nicola Mottola the newly appointed

CFO

Testo del comunicato

Vedi allegato

Press release

OTOFARMA: NICOLA MOTTOLA NEW CHIEF FINANCIAL OFFICER

The manager brings high-profile expertise in financial management, economic and financial governance, and reporting processes to the company

Naples, 8 January 2026 – Otofarma – a leading group in the production of hearing aids distributed mainly through the pharmaceutical channel, with over 30 years of experience in the hearing care sector – announces the arrival of Nicola Mottola as Chief Financial Officer. The appointment of the new CFO is part of a broader process of strengthening the company's management structure, aimed at supporting the growth and evolution of Otofarma's organisational and industrial model.

With solid experience in administration, finance, control and consolidated financial statements gained in structured and international industrial contexts, Nicola Mottola brings to Otofarma highprofile skills in financial management, economic and financial governance and reporting processes. Throughout his career, he has held positions of increasing responsibility, coordinating finance teams and interacting with internal and external stakeholders, including auditors, consultants and top management, contributing to accounting harmonisation projects, process efficiency and strategic decision support.

With a degree in Economics and Management, Mottola began his professional career in 2010 at PWC as an Auditor, then moved to Proma Spa in 2015 as Head of Management Control and to Zeta Consulting in 2019 as Senior Consultant. Finally, before joining Otofarma, he worked at Seda International Packaging Group from 2021 to 2025 as Group Accounting and Tax Manager, Consolidated Financial Statements Manager and Corporate Treasury and Finance Manager.

The arrival of Mr Mottola represents an important step in Otofarma's development, as it continues to consolidate its management team with determination in order to tackle the next stages of growth. In this context, Dr Giulia Simone, who has contributed to the company's growth since its inception with her professionalism and whose advice and support have been invaluable during the IPO phase and in the months immediately following the listing, will remain member of the Board of the Directors and will continue to play a key role, ensuring continuity and support in the company's development, particularly in the implementation of the Convergence 2.0 Project, which is central to the company's growth path and has already been launched.

Giovanna Incarnato Bartolomucci, CEO of Otofarma, commented, 'Thanks also to the support provided by Dr. Mottola's expertise, Otofarma will be able to achieve and ensure a solid and structured level of governance and management control that will support the company in achieving its sustainable development and value creation objectives in the medium to long term.'

***

The Company uses the EMARKET SDIR and STORAGE circuit, managed by Teleborsa, for the dissemination of Regulated Information. This system is authorized by CONSOB by resolutions No. 22517 and No. 22518 of November 23, 2022, pursuant to Article 113-ter, paragraph 4, letter a, of Legislative Decree No. 58/1998. For further information on the greenshoe option, please refer to the admission document available in the Investor Relations section of the website www.otofarmaspa.com.

Identification Codes

Alphanumeric Code: OTO

ISIN for Ordinary Shares: IT0005663361

***

About Otofarma SpA

Otofarma Group is a leader in the design, production, and distribution of customized hearing aids through pharmacies. Its reputation is built on technological innovation and continuous research, offering advanced audiological solutions at a guaranteed democratic price, with the goal of making hearing care more accessible and widespread.

Pioneering in telemedicine, Otofarma was the first company in Europe to introduce specialist tele-audiology services in pharmacies, today available under Otofarma brand in more 4,000 partner pharmacies, making access to diagnosis and personalized devices easier.

Founded by Gennaro Bartolomucci, now Chairman, and led by CEO Giovanna Incarnato Bartolomucci, the company holds six patents for its proprietary software and instruments. Its devices and services are distributed exclusively through partner pharmacies, ensuring a controlled, quality-focused business model.

For more information:

Otofarma S.p.A.- Investor relations

Anna Incarnato Bartolomucci E-mail: investor.relations@otofarma.it

mob: +39 347 0506780

Alantra – Euronext Growth Advisor

E-mail: ega@alantra.com mob: +39 334 6267242

SEC Newgate – Media Relations

+39 02 624 999 1

Michele Bon – michele.bon@secnewgate.it – +39 338 693 3868

Francesca Brambilla – francesca.brambilla@secnewgate.it – +39 338 627 2146